Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun A Fleming, Chun Yew Fong, Uma Borate, Meagan A Jacoby, Daniel Nowak, Maria R Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood blood.2024025464.

https://doi.org/10.1182/blood.2024025464

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)

Lukas Peter Frenzel, Laura Beckmann, Sandra Robrecht, Can Zhang, Anna Maria Fink, Othman Al-Sawaf, Christof Schneider, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Tim H. H. Brummendorf, Michael Hallek, Barbara F. Eichhorst, Kirsten Fischer, Fabian Beier, Susanne Isfort

Blood (2024) 144 (Supplement 1): 3250.

https://doi.org/10.1182/blood-2024-200075

Published: 2024

Journal Articles

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Blood (2024) 144 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2024-208727

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Rachel Cook, Meagan Jacoby, Daniel Nowak, Brenda Chyla, Ying Zhou, Grace Ku, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 319.

https://doi.org/10.1182/blood-2023-189446

Published: 2023

Journal Articles

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Rosemary Anne Harrup, Arnon P. Kater, Barbara F. Eichhorst, Carolyn Owen, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Yi Meng Chang, Rosemary Millen, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, John F. Seymour

Blood (2023) 142 (Supplement 1): 1898.

https://doi.org/10.1182/blood-2023-177567

Published: 2023

Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood (2022) 140 (25): 2754–2756.

https://doi.org/10.1182/blood.2022016963

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 529–531.

https://doi.org/10.1182/blood-2022-158518

Published: 2022

Journal Articles

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Vanessa E. Kennedy, Cheryl Peretz, Paul Lee, Brenda Chyla, Yan Sun, Monique Dail, Jason Hill, Elaine Tran, Andrew Koh, Jessica K. Altman, Naval Daver, Mark J. Levis, James McCloskey, Alexander Perl, Catherine Smith

Blood (2022) 140 (Supplement 1): 2244–2246.

https://doi.org/10.1182/blood-2022-160304

Published: 2022

Journal Articles

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Recher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 1441–1444.

https://doi.org/10.1182/blood-2022-169509

Published: 2022

Journal Articles

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Arnon P. Kater, Barbara Eichhorst, Carolyn Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani-Mulero, John F. Seymour

Blood (2022) 140 (Supplement 1): 7010–7012.

https://doi.org/10.1182/blood-2022-158275

Published: 2022

Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood (2022) 140 (8): 839–850.

https://doi.org/10.1182/blood.2021015014

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Matthew S. Davids, Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai, Brenda Chyla, Kavita Sail, John Pesko, Madhavi Pai, Viktor Komlosi, Michael Hallek, Jennifer R. Brown, Othman Al-Sawaf

Blood (2021) 138 (Supplement 1): 2634.

https://doi.org/10.1182/blood-2021-153033

Published: 2021

Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2021-147258

Published: 2021

Journal Articles

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F. Seymour, Jenny Qun Wu, Relja Popovic, Barbara Eichhorst, Peter Hillmen, Thomas J. Kipps, Anton W. Langerak, Carolyn Owen, Julie Dubois, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Fengjiao Dunbar, Yanwen Jiang, Brenda Chyla, Michelle Boyer, Maria Thadani-Mulero, Marcus Lefebure, Rosemary Harrup, Arnon P. Kater

Blood (2021) 138 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2021-147731

Published: 2021

Journal Articles

Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

Arnon P. Kater, Tong Lu, Anton W. Langerak, Clemens Mellink, Brenda Chyla, Jenny Qun Wu, Michelle Boyer, Marcus Lefebure, Yanwen Jiang, John F. Seymour

Blood (2021) 138 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2021-148612

Published: 2021

Journal Articles

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod A. Pullarkat, Brian A. Jonas, Christian Recher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo

Blood (2021) 138 (Supplement 1): 224.

https://doi.org/10.1182/blood-2021-145639

Published: 2021

Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts

Blood (2021) 138 (10): 836–846.

https://doi.org/10.1182/blood.2020009578

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

NARROW

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only